Urgent Evaluation of Pediatric Cytopenias with Eosinophilia and Lymphocytosis

Diagnostic Workup

Peripheral blood smear review by a hematopathologist is mandatory to detect blasts, abnormal white‑cell morphology, red‑cell poikilocytosis, schistocytes, or giant platelets. 1
A repeat complete blood count with differential should be obtained to confirm the initial abnormalities and to assess hemoglobin level. 2
Bone‑marrow aspiration and biopsy are indicated when the peripheral smear shows atypical or immature cells, abnormal morphology, or when more than one hematologic cell line is affected. 2

The combination of neutropenia with eosinophilia and lymphocytosis is not typical of isolated neutropenia or immune thrombocytopenia and therefore warrants bone‑marrow assessment. 1
Leukocytosis or leukopenia accompanied by immature or abnormal cells is inconsistent with benign diagnoses. 1
Presence of multiple cytopenias or abnormal cell populations suggests underlying bone‑marrow pathology. 2
Such a pattern may represent early acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or other myeloproliferative/myelodysplastic disorders. 4

Acute Myeloid Leukemia (AML): Certain AML subtypes with core‑binding factor abnormalities can present with cytopenias and eosinophilia; diagnosis requires bone‑marrow aspirate/biopsy with flow cytometry, plus cytogenetic and molecular testing for fusion genes (e.g., RUNX1‑RUNX1T1, CBFB‑MYH11, PML‑RARA, MLL rearrangements).** 3
Chronic Myeloid Leukemia (CML): Although CML often shows leukocytosis, it can present with variable counts and eosinophilia; BCR::ABL1 fusion testing (Philadelphia chromosome) is essential, and CML‑chronic phase may manifest a broad spectrum of complications that need urgent recognition.** 4

Assess for bleeding manifestations (petechiae, purpura, mucosal bleeding, or signs of intracranial hemorrhage). 1
Screen for leukostasis symptoms (headache, visual changes, respiratory distress, or priapism) and intervene emergently if present. 4

Coagulation studies (PT, aPTT) to exclude concurrent clotting abnormalities. 6
Basic metabolic panel and liver function tests to evaluate for tumor‑lysis syndrome or organ dysfunction. 4
Serum lactate dehydrogenase and uric acid when leukemia is suspected. 4

Bone‑marrow aspirate and biopsy with morphologic examination, flow cytometry, karyotype, and molecular testing for fusion genes and mutations. 3
BCR::ABL1 testing (quantitative PCR or FISH) to exclude CML. 4

Hospitalize patients with severe neutropenia (ANC < 500 µL⁻¹), especially if fever or bleeding is present. 2
Reserve platelet transfusions for active bleeding or platelet counts < 10,000 µL⁻¹ with high bleeding risk. 2
Restrict high‑risk activities (e.g., contact sports, activities with head‑trauma potential). 6
Educate caregivers on warning signs such as persistent fever, worsening bleeding, altered mental status, or severe headache. 6

Do not assume a benign etiology (e.g., ethnic neutropenia) without first excluding malignancy.
Do not delay bone‑marrow examination; multi‑lineage abnormalities mandate direct marrow assessment. 1
Do not attribute findings solely to viral infection without peripheral‑smear review and close follow‑up, as early leukemia can be missed.
Do not initiate empiric corticosteroids before a definitive diagnosis, because steroids may obscure leukemic cells. 2

If initial workup excludes acute leukemia and bone marrow is normal, repeat CBC in 1–2 weeks to monitor for resolution.
For neutropenia persisting > 3–6 months without a diagnosis, evaluate antinuclear antibodies, immunoglobulin levels, and antineutrophil antibodies. 2